Tag: radioembolization

Hotly debated across the Society of Interventional Oncology (SIO; 25–29 January 2024, Long Beach, USA) annual conference programme, speakers took to the stage to...

Interventional News’ most read stories in October included significant data releases from TCT 2023 (23–26 October, San Francisco, USA); results from a study investigating sex...

ABK Biomedical has received approval for its investigational device exemption (IDE) application from the US Food and Drug Administration (FDA) to commence a multicentre...

After the disappointment of a few failed randomised controlled trials (RCTs), transarterial radioembolization (TARE) is finally back in the spotlight. And interventional radiologists (IRs)...

At the Society of Interventional Radiology (SIR) 2022 Annual Meeting (11-16 June, Boston, USA), four of the abstracts submitted were declared ‘Abstract of the...

Using selective internal radiation therapy (SIRT) to down-stage hepatocellular carcinoma (HCC) tumours or act as a bridge to surgery is feasible for both small...

Delineating the path towards personalised dosimetry in order to “maximise response to therapy”, David McNiel (University of Arizona Health Sciences, Tucson, USA) presented clinical...

Personalised treatment selection and planning based on controlled dosimetry will lead to improvements in treatment accuracy. This is the conclusion presented by Marnix Lam...

As presented at the Global Embolization Oncology Symposium Technologies (GEST) 2020 meeting (4–6 September, virtual), Robert Lewandowski discusses the evolution of radioembolization with Yttrium-90...

Sirtex Medical reports that enrollment in the US RESiN registry has reached a milestone of 1,650 patients and 12.8 months of follow-up, allowing for...

In an entirely new endeavour for Yttrium-90 (Y-90) radioembolization, investigators from Northwestern University, Chicago, USA, have used the technique for the treatment of prostate...

The cover of June’s edition of the Journal of Hepatology featured a paper on transarterial radioembolization for the treatment of hepatocellular carcinoma (HCC). Publication...

This article is sponsored by Terumo. The first prospective study on the combination of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and Holmium-166 (166Ho) radioembolization...

A proof-of-concept study has demonstrated the feasibility of using computed tomography (CT) with a novel composition of radiopaque microspheres in Yttrium-90 (Y-90) radioembolization to...

Patients have a strong preference for transradial access, a recent study published in the Journal of Vascular and Interventional Radiology finds. Lead author Lisa...

Encouraging results from Y90 (yttrium-90) radioembolization of pancreatic cancer support a possible role for it in the management of the disease, with initial small...

Coil embolization of hepatic arteries to induce redistribution of blood flow and microspheres has a mediocre success rate, concluded a recent study presented by...

A recent session at CIRSE 2018 sought to go beyond the headline findings from a number of recent randomised controlled trials (RCTs) in interventional...

Radiation segmentectomy is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. One-, three-, and five-year overall survival probability was 100%, 82% and 75% in patients with a baseline tumour size of 3cm or less.

Varian Medical has announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical for A$28 per share in cash....

Dosimetry, within the context of selective internal radiation therapy (SIRT) using Y-90 microspheres, is typically understood to be the measurement and calculation of the...

Metastatic colorectal cancer patients treated first-line with SIR-spheres Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, the REsect study...

The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...

Terumo Europe NV has announced the first commercial clinical case using Quiremspheres—the next generation radioembolization microspheres for advanced unresectable liver cancer. Quiremspheres are the only...

Y-90 radioembolization is a promising locoregional therapy for a devastating disease with few available treatment options. Ongoing and future clinical trials will help to...

Most complications related to Y-90 therapy may be prevented or mitigated with appropriate patient selection, careful pretreatment planning, meticulous procedural technique, and optimisation of...

BTG and Mirada Medical announced CE mark certification for the Simplicit90Y dosimetry software, designed to optimise the planning of Y-90 selective internal radiation therapy...

New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma. Sirtex has announced...